922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Saved in:
| Title: | 922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. |
|---|---|
| Authors: | Song, Z.1 (AUTHOR), Park, J.2 (AUTHOR), Zhang, Y.3 (AUTHOR), Coward, J.4 (AUTHOR), Voskoboynik, M.5 (AUTHOR), Kichenadasse, G.6 (AUTHOR), Parakh, S.7 (AUTHOR), Powderly, J.8 (AUTHOR), Lin, R.9 (AUTHOR), Lin, X.10 (AUTHOR), Wei, T.11 (AUTHOR), Qu, S.12 (AUTHOR), Richardson, G.13 (AUTHOR), Guo, Y.14 (AUTHOR), Orr, D.15 (AUTHOR), Yu, X.1 (AUTHOR), Shen, L.16 (AUTHOR), Liu, S.17 (AUTHOR), Huang, Y.18 (AUTHOR), Liu, S-H.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS603-S603. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189419304 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Song%2C+Z%2E%22">Song, Z.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Park%2C+J%2E%22">Park, J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhang%2C+Y%2E%22">Zhang, Y.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coward%2C+J%2E%22">Coward, J.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Voskoboynik%2C+M%2E%22">Voskoboynik, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kichenadasse%2C+G%2E%22">Kichenadasse, G.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Parakh%2C+S%2E%22">Parakh, S.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Powderly%2C+J%2E%22">Powderly, J.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lin%2C+R%2E%22">Lin, R.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lin%2C+X%2E%22">Lin, X.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wei%2C+T%2E%22">Wei, T.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Qu%2C+S%2E%22">Qu, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Richardson%2C+G%2E%22">Richardson, G.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Guo%2C+Y%2E%22">Guo, Y.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Orr%2C+D%2E%22">Orr, D.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yu%2C+X%2E%22">Yu, X.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shen%2C+L%2E%22">Shen, L.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+S%2E%22">Liu, S.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Huang%2C+Y%2E%22">Huang, Y.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+S-H%2E%22">Liu, S-H.</searchLink><relatesTo>17</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS603-S603. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189419304 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.1491 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S603 Titles: – TitleFull: 922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Song, Z. – PersonEntity: Name: NameFull: Park, J. – PersonEntity: Name: NameFull: Zhang, Y. – PersonEntity: Name: NameFull: Coward, J. – PersonEntity: Name: NameFull: Voskoboynik, M. – PersonEntity: Name: NameFull: Kichenadasse, G. – PersonEntity: Name: NameFull: Parakh, S. – PersonEntity: Name: NameFull: Powderly, J. – PersonEntity: Name: NameFull: Lin, R. – PersonEntity: Name: NameFull: Lin, X. – PersonEntity: Name: NameFull: Wei, T. – PersonEntity: Name: NameFull: Qu, S. – PersonEntity: Name: NameFull: Richardson, G. – PersonEntity: Name: NameFull: Guo, Y. – PersonEntity: Name: NameFull: Orr, D. – PersonEntity: Name: NameFull: Yu, X. – PersonEntity: Name: NameFull: Shen, L. – PersonEntity: Name: NameFull: Liu, S. – PersonEntity: Name: NameFull: Huang, Y. – PersonEntity: Name: NameFull: Liu, S-H. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
